Structure-inspired Design of β-arrestin-biased Ligands for Aminergic GPCRs

Overview

Journal Nat Chem Biol

Specialties Biochemistry
Biology
Chemistry

Date 2017 Dec 12

PMID 29227473

Citations 87

Authors

John D McCorvy

Kyle V Butler

Brendan Kelly

Katie Rechsteiner

Joel Karpiak

Robin M Betz

Bethany L Kormos

Brian K Shoichet

Ron O Dror

Jian Jin

Bryan L Roth

Affiliations

Soon will be listed here.

Abstract

Development of biased ligands targeting G protein-coupled receptors (GPCRs) is a promising approach for current drug discovery. Although structure-based drug design of biased agonists remains challenging even with an abundance of GPCR crystal structures, we present an approach for translating GPCR structural data into β-arrestin-biased ligands for aminergic GPCRs. We identified specific amino acid-ligand contacts at transmembrane helix 5 (TM5) and extracellular loop 2 (EL2) responsible for Gi/o and β-arrestin signaling, respectively, and targeted those residues to develop biased ligands. For these ligands, we found that bias is conserved at other aminergic GPCRs that retain similar residues at TM5 and EL2. Our approach provides a template for generating arrestin-biased ligands by modifying predicted ligand interactions that block TM5 interactions and promote EL2 interactions. This strategy may facilitate the structure-guided design of arrestin-biased ligands at other GPCRs, including polypharmacological biased ligands.

Citing Articles

Ligand-Induced Biased Activation of GPCRs: Recent Advances and New Directions from In Silico Approaches.

Hashem S, Dougha A, Tuffery P Molecules. 2025; 30(5).

PMID: 40076272 PMC: 11901715. DOI: 10.3390/molecules30051047.

Systematic analysis of biomolecular conformational ensembles with PENSA.

Vogele M, Thomson N, Truong S, McAvity J, Zachariae U, Dror R J Chem Phys. 2025; 162(1).

PMID: 39745157 PMC: 11698571. DOI: 10.1063/5.0235544.

Biased Signaling Agonists Promote Distinct Phosphorylation and Conformational States of the Dopamine D3 Receptor.

Nepal B, Barnett J, Bearoff F, Kortagere S Int J Mol Sci. 2024; 25(19).

PMID: 39408798 PMC: 11476979. DOI: 10.3390/ijms251910470.

G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery.

Zhang M, Chen T, Lu X, Lan X, Chen Z, Lu S Signal Transduct Target Ther. 2024; 9(1):88.

PMID: 38594257 PMC: 11004190. DOI: 10.1038/s41392-024-01803-6.

Peptide-derived ligands for the discovery of safer opioid analgesics.

Eliasof A, Liu-Chen L, Li Y Drug Discov Today. 2024; 29(5):103950.

PMID: 38514040 PMC: 11127667. DOI: 10.1016/j.drudis.2024.103950.

References

Best R, Zhu X, Shim J, Lopes P, Mittal J, Feig M . Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles. J Chem Theory Comput. 2013; 8(9):3257-3273. PMC: 3549273. DOI: 10.1021/ct300400x. View

Rasmussen S, DeVree B, Zou Y, Kruse A, Chung K, Kobilka T . Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature. 2011; 477(7366):549-55. PMC: 3184188. DOI: 10.1038/nature10361. View

Zhang L, Hermans J . Hydrophilicity of cavities in proteins. Proteins. 1996; 24(4):433-8. DOI: 10.1002/(SICI)1097-0134(199604)24:4<433::AID-PROT3>3.0.CO;2-F. View

Kobilka B, Schertler G . New G-protein-coupled receptor crystal structures: insights and limitations. Trends Pharmacol Sci. 2008; 29(2):79-83. DOI: 10.1016/j.tips.2007.11.009. View

Gesty-Palmer D, Yuan L, Martin B, Wood 3rd W, Lee M, Janech M . β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo. Mol Endocrinol. 2013; 27(2):296-314. PMC: 3683806. DOI: 10.1210/me.2012-1091. View

Overington J, Al-Lazikani B, Hopkins A . How many drug targets are there?. Nat Rev Drug Discov. 2006; 5(12):993-6. DOI: 10.1038/nrd2199. View

Betz R, Walker R . Paramfit: automated optimization of force field parameters for molecular dynamics simulations. J Comput Chem. 2014; 36(2):79-87. DOI: 10.1002/jcc.23775. View

Ambrosio C, Molinari P, Cotecchia S, Costa T . Catechol-binding serines of beta(2)-adrenergic receptors control the equilibrium between active and inactive receptor states. Mol Pharmacol. 2000; 57(1):198-210. View

Charfi I, Audet N, Bagheri Tudashki H, Pineyro G . Identifying ligand-specific signalling within biased responses: focus on δ opioid receptor ligands. Br J Pharmacol. 2014; 172(2):435-48. PMC: 4292958. DOI: 10.1111/bph.12705. View

10.

Luedtke R, Mishra Y, Wang Q, Griffin S, Bell-Horner C, Taylor M . Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds. ACS Chem Neurosci. 2012; 3(12):1050-62. PMC: 3526968. DOI: 10.1021/cn300142q. View

11.

Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu J, Gainetdinov R . Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A. 2008; 105(36):13656-61. PMC: 2533245. DOI: 10.1073/pnas.0803522105. View

12.

Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, Novick S . A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci. 2012; 3(3):193-203. PMC: 3369801. DOI: 10.1021/cn200111m. View

13.

Shapiro D, Renock S, Arrington E, Chiodo L, Liu L, Sibley D . Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003; 28(8):1400-11. DOI: 10.1038/sj.npp.1300203. View

14.

Isogai S, Deupi X, Opitz C, Heydenreich F, Tsai C, Brueckner F . Backbone NMR reveals allosteric signal transduction networks in the β1-adrenergic receptor. Nature. 2016; 530(7589):237-41. DOI: 10.1038/nature16577. View

15.

Besnard J, Ruda G, Setola V, Abecassis K, Rodriguiz R, Huang X . Automated design of ligands to polypharmacological profiles. Nature. 2012; 492(7428):215-20. PMC: 3653568. DOI: 10.1038/nature11691. View

16.

Weiss D, Ahn S, Sassano M, Kleist A, Zhu X, Strachan R . Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptor. ACS Chem Biol. 2013; 8(5):1018-26. PMC: 3658555. DOI: 10.1021/cb400103f. View

17.

Motulsky H, Mahan L . The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol. 1984; 25(1):1-9. View

18.

Manglik A, Lin H, Aryal D, McCorvy J, Dengler D, Corder G . Structure-based discovery of opioid analgesics with reduced side effects. Nature. 2016; 537(7619):185-190. PMC: 5161585. DOI: 10.1038/nature19112. View

19.

Fowler J, Bhattacharya S, Urban J, Vaidehi N, Mailman R . Receptor conformations involved in dopamine D(2L) receptor functional selectivity induced by selected transmembrane-5 serine mutations. Mol Pharmacol. 2012; 81(6):820-31. PMC: 3362898. DOI: 10.1124/mol.111.075457. View

20.

Wadenberg M, Soliman A, VanderSpek S, Kapur S . Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology. 2001; 25(5):633-41. DOI: 10.1016/S0893-133X(01)00261-5. View